Approximately 60% of pharmaceutical end products in Vietnam are imported
Your DAV Gateway
Why Vietnam Exceptional Growth in Import-Dominant Pharmaceutical Market Rapid Market Growth & Import Opportunities
As of 2020, the Vietnamese pharmaceutical market was valued at approximately US$10 billion, showcasing rapid growth and substantial potential for both local and imported drugs.
Regional markets we support
Import Market Dominance
Import market constitutes approximately US$6 billion in 2020
Anticipated growth reaching US$9.66 billion by 2026
Strong market credibility and desirability for imported pharmaceuticals
Market Structure & Opportunities
The Vietnamese pharmaceutical landscape presents unique opportunities
Key points
60% imported pharmaceuticals demonstrating market openness
40% locally produced drugs complementing the market
Import dominance elevating credibility and desirability of international pharmaceutical brands
Strong consumer confidence in imported pharmaceutical products
Regulatory Framework Structure
The regulatory framework is overseen by the Drug Administration of Vietnam (DAV) under the Ministry of Health, ensuring comprehensive oversight of:
DAV Regulatory Responsibilities
Safety, efficacy, and quality control for all pharmaceutical products
Marketing authorization and product registration processes
Import licensing and compliance monitoring
Post-market surveillance and pharmacovigilance
Current Regulatory Environment
Do not let regulatory complexity delay your entry into Vietnam's rapidly growing pharmaceutical market. Our Vietnam-based regulatory experts, with deep DAV knowledge and proven track record, are ready to accelerate your market access in this import-dominant market projected to reach US$9.66 billion by 2026.
Contact us today to discuss how our Vietnam expertise can unlock opportunities in Southeast Asia's fastest-growing pharmaceutical market.
Our team documents assumptions, authority expectations, and decision points so sponsors can approve the plan with clear risk ownership.
Local pharmacists and regulatory specialists stay accountable through query cycles, inspection readiness, and post-approval obligations.
We align labeling, Module 1 localization, and partner communications so commercial launch can follow approval without rework.
Where pathways differ by product class, we sequence filings to protect the critical path and avoid avoidable deficiency letters.
Engagements can scale from a single dossier workstream to a multi-country virtual regulatory function.
PECAN.Solutions scopes each workstream with milestones, document owners, and authority touchpoints so registration, license holding, and commercial access stay on one plan.
Key points
Bureaucratic hurdles requiring expert navigation
Prolonged timelines within the DAV system
Complex documentation and submission requirements
Potential delays that may hinder timely product innovations
Striking balance between affordability and drug safety remains a persistent challenge
Ongoing modernization efforts to improve regulatory efficiency
Government commitment to streamlining approval processes
Technological integration initiatives to reduce bureaucratic barriers